The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers USD 3.5 billion each year.
The verdict, handed down Friday in federal court in Boston, is the first time a jury has decided such a case since the US Supreme Court ruled last year that so-called "pay-for-delay" settlements may run afoul of antitrust laws.
The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers USD 3.5 billion each year.
An attorney for the plaintiffs, which include drug wholesalers, retailers and insurers, could not be reached for comment. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict.
The lawsuit, which began in 2012, challenged a 2008 settlement in a patent suit between AstraZeneca and Ranbaxy. The plaintiffs claim the settlement gave Ranbaxy nearly USD 1 billion to delay the launch of its generic Nexium.
The suit originally also targeted two other generic drugmakers that reached deals with AstraZeneca over Nexium, namely Teva Pharmaceutical Industries Ltd and Dr Reddy's Laboratories Ltd , but both settled with the plaintiffs.
Two other cases against the same four companies over the Nexium settlements are pending in Pennsylvania state court. Those cases are not affected by Friday's verdict.
Ranbaxy had planned to launch generic Nexium this year, but the FDA recently revoked its approval, citing problems with the company's manufacturing process.
The case is In re Nexium Antitrust Litigation, US District Court for the District of Massachusetts, No. 12-2409.
(Reporting By Brendan Pierson; Editing by Ted Botha and Andrew Hay)
Ranbaxy Labs stock price
On December 05, 2014, Ranbaxy Laboratories closed at Rs 618.45, down Rs 9.1, or 1.45 percent. The 52-week high of the share was Rs 697.50 and the 52-week low was Rs 306.05.
The company's trailing 12-month (TTM) EPS was at Rs 20.91 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 29.58. The latest book value of the company is Rs 25.82 per share. At current value, the price-to-book value of the company is 23.95.
Anda sedang membaca artikel tentang
AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
Dengan url
http://kebugaranhidup.blogspot.com/2014/12/astrazeneca-ranbaxy-prevail-in-nexium.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
namun jangan lupa untuk meletakkan link
AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
sebagai sumbernya
0 komentar:
Posting Komentar